Heart disease drug available for NHS patients

The introduction of inclisiran on the NHS has been approved following an agreement with Novatis, providing the potential to save up to 30,000 lives over the next 10 years.

The yet to be approved drug inclisiran, a treatment to lower cholesterol, will be studied in UK patients as part of a large-scale NHS clinical trial expected to start later this year. The drug is expected to be available through a population-level agreement, considered a world-first, with the the Department of Health and Social Care stating that this is pioneering a game-changing approach to reducing the risk of heart disease.

Heart disease is the world’s biggest killer and the second biggest cause of death in the UK. Early results from clinical trials suggest that if inclisiran is given to 300,000 patients annually, it could help prevent 55,000 heart attacks and strokes, and has the potential of saving 30,000 lives in the next 10 years. The bi-annual injection, is expected to be filed for approval as a preventative add-on treatment to statins for patients who have already been diagnosed with cardiovascular disease later this year.

Health and Social Care Secretary Matt Hancock said: “As Health Secretary, I’m determined find ways to save as many lives as possible, and to do my best to stop terrible conditions like heart disease from taking people from their family and friends far too soon.

“This partnership is fantastic news and is a huge stride forwards in helping to achieve this. This collaboration has the potential to save 30,000 lives over the next 10 years and is proof that the UK continues to be the world-leading destination for revolutionary healthcare. I will always help the NHS reach its full potential, and novel and innovative collaborations such as this put patients at the forefront of the most promising medical breakthroughs.”